Added to YB: 2026-05-11
Pitch date: 2026-05-07
NVO [neutral]
Novo Nordisk A/S
-1.16%
current return
Author Info
HatedMoats identifies hated moats. I buy companies when the market panics. Contrarian investor focused on quality, value & long-term growth. Sign up for the newsletter.
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Market Cap
DKK 1.3T
Pitch Price
DKK 293.70
Price Target
74.00 (-75%)
Dividend
4.03%
EV/EBITDA
8.04
P/E
10.59
EV/Sales
4.31
Sector
Pharmaceuticals
Category
value
Novo Nordisk Q1 2026 Review: The Reset Year Looks Less Ugly Than Feared
NVO (earnings): Q1 adj sales -4% at CER (better than -5% to -13% guide), adj op profit -6%. US -11% on pricing, diabetes -12%, but obesity +22% driven by intl (+44%). Wegovy pill launched strong w/ 1.3M scripts Q1, DKK 2.3B sales. Wegovy HD approved (20.7% weight loss). Guide raised to -4% to -12% sales (from -5% to -13%). Still navigating pricing reset, Lilly competition & margin pressure. DCF intrinsic value $74/ADR unchanged. Moat bruised not broken.
Read full article (11 min)